<DOC>
	<DOCNO>NCT00144105</DOCNO>
	<brief_summary>Evaluation safety efficacy Tipranavir ( TPV ) boost Ritonavir ( RTV ) versus active control arm ( Lopinavir / RTV ) antiretroviral ( ARV ) therapy naïve HIV-1 infect patient</brief_summary>
	<brief_title>A Randomised Trial Evaluate Antiviral Efficacy Safety Treatment With 500 mg Tipranavir ( TPV ) Plus 100 mg 200 mg Ritonavir ( RTV ) p.o . BID Comparison 400 mg Lopinavir ( LPV ) Plus 100 mg RTV p.o . BID Combination With Standard Background Regimen ARV Therapy naïve Patients .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1 . Signed informed consent prior trial participation . 2 . HIV1 infect male female &gt; = 18 year age . 3 . No previous ARV therapy . 4 . Any CD4+ T lymphocyte count &lt; 500 cell / µl . 5 . HIV1 viral load &gt; = 5000 copies/mL screen . 6 . Screening laboratory value indicate adequate baseline organ function . 7 . A prior AIDS defining event acceptable long resolve subject stable treatment ( e.g . opportunistic infection ; ARV ) least 2 week screen Exclusion criterion : 1 . Female patient childbearing potential : positive serum pregnancy test screening study , breast feeding , plan become pregnant 2 . Use investigational medication within 30 day study entry trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>